Cancer patients monitored for 15 years after groundbreaking gene treatments
NCT ID NCT00923026
Summary
This study follows patients for up to 15 years after they received experimental gene therapies for cancers like melanoma and neuroendocrine tumors. The goal is to monitor long-term safety and health outcomes, as required by the FDA. Participants will have regular check-ups, blood tests, and occasional imaging to track their health over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.